Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia
NCT ID: NCT00797797
Last Updated: 2011-02-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
364 participants
INTERVENTIONAL
2008-11-30
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Milnacipran on Pain in Fibromyalgia
NCT01288807
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia
NCT01077375
Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran
NCT00757679
Study of Milnacipran for the Treatment of Fibromyalgia
NCT00314249
Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial
NCT01829243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Milnacipran Added
Milnacipran Added
Milnacipran 100 mg/d added
No Treatment Added
No Treatment Added
No added treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Treatment Added
No added treatment
Milnacipran Added
Milnacipran 100 mg/d added
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* tolerate at least 300 mg/day of pregabalin
* have an incomplete response to pregabalin treatment
Exclusion Criteria
* substance abuse
* pulmonary dysfunction
* renal impairment
* active cardiac disease
* liver disease
* narrow angle glaucoma
* autoimmune disease
* cancer
* inflammatory bowel disease
* unstable endocrine disease
* prostatic enlargement
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Forest Research Institute Inc (A Subsidiary of Forest Laboratories Inc)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patricia D'Astoli
Role: STUDY_DIRECTOR
Forest Research Institute, a subsidiary of Forest Laboratories, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Forest Investigative Site
Birmingham, Alabama, United States
Forest Investigative Site
Mesa, Arizona, United States
Forest Investigative Site
Peoria, Arizona, United States
Forest Investigative Site
Hot Springs, Arkansas, United States
Forest Investigative Site
Anaheim, California, United States
Forest Investigative Site
Sacramento, California, United States
Forest Investigative Site
Sacramento, California, United States
Forest Investigative Site
Torrance, California, United States
Forest Investigative Site
Walnut Creek, California, United States
Forest Investigative Site
Denver, Colorado, United States
Forest Investigative Site
Cromwell, Connecticut, United States
Forest Investigative Site
Danbury, Connecticut, United States
Forest Investigative Site
Clearwater, Florida, United States
Forest Investigative Site
Daytona Beach, Florida, United States
Forest Investigative Site
Delray Beach, Florida, United States
Forest Investigative Site
Fort Myers, Florida, United States
Forest Investigative Site
Jacksonville, Florida, United States
Forest Investigative Site
Miami, Florida, United States
Forest Investigative Site
Ocala, Florida, United States
Forest Investigative Site Orl2
Orlando, Florida, United States
Forest Investigative Site
Orlando, Florida, United States
Forest Investigative Site
Ormond Beach, Florida, United States
Forest Investigative Site PP1
Pembroke Pines, Florida, United States
Forest Investigative Site PP2
Pembroke Pines, Florida, United States
Forest Investigative Site
Pismo Beach, Florida, United States
Forest Investigative Site
St. Petersburg, Florida, United States
Forest Investigative Site
Tampa, Florida, United States
Forest Investigative Site
Atlanta, Georgia, United States
Forest Investigative Site
Honolulu, Hawaii, United States
Forest Investigative Site
Couer D'Alene, Idaho, United States
Forest Investigative Site
Evansville, Indiana, United States
Forest Investigative Site
Indianapolis, Indiana, United States
Forest Investigative Site
Indianapolis, Indiana, United States
Forest Investigative Site
Baltimore, Maryland, United States
Forest Investigative Site
No. Dartmouth, Massachusetts, United States
Forest Investigative Site
Worcester, Massachusetts, United States
Forest Investigative Site
Jackson, Mississippi, United States
Forest Investigative Site
St Louis, Missouri, United States
Forest Investigative Site
Omaha, Nebraska, United States
Forest Investigative Site
Albuquerque, New Mexico, United States
Forest Investigative Site
Syracuse, New York, United States
Forest Investigative Site
Cincinnati, Ohio, United States
Forest Investigative Site
Cleveland, Ohio, United States
Forest Investigative Site
Eugene, Oregon, United States
Forest Investigative Site
Medford, Oregon, United States
Forest Investigative Site
Portland, Oregon, United States
Forest Investigative Site
Greer, South Carolina, United States
Forest Investigative Site
Memphis, Tennessee, United States
Forest Investigative Site
Houston, Texas, United States
Forest Investigative Site
Houston, Texas, United States
Forest Investigative Site
Lake Jackson, Texas, United States
Forest Investigative Site
Salt Lake City, Utah, United States
Forest Investigative Site
Salt Lake City, Utah, United States
Forest Investigative Site
Woodstock, Vermont, United States
Forest Investigative Site
Bellevue, Washington, United States
Forest Investigative Site
Bellingham, Washington, United States
Forest Investigative Site SEA1
Seattle, Washington, United States
Forest Investigative Site SEA2
Seattle, Washington, United States
Forest Investigative Site
Spokane, Washington, United States
Forest Investigative Site
Racine, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MLN-MD-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.